Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Income from Continuing Operations (2021 - 2025)

Kezar Life Sciences' Income from Continuing Operations history spans 5 years, with the latest figure at 10689000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 47.38% year-over-year to 10689000.0; the TTM value through Sep 2025 reached 61167000.0, up 36.14%, while the annual FY2024 figure was 83736000.0, 17.8% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 10689000.0 at Kezar Life Sciences, up from 13704000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 10689000.0 in Q3 2025 and bottomed at 32260000.0 in Q4 2023.
  • The 5-year median for Income from Continuing Operations is 17847000.0 (2022), against an average of 18390736.84.
  • The largest annual shift saw Income from Continuing Operations crashed 77.44% in 2023 before it soared 47.38% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 14212000.0 in 2021, then dropped by 27.93% to 18181000.0 in 2022, then plummeted by 77.44% to 32260000.0 in 2023, then soared by 37.33% to 20218000.0 in 2024, then skyrocketed by 47.13% to 10689000.0 in 2025.
  • Per Business Quant, the three most recent readings for KZR's Income from Continuing Operations are 10689000.0 (Q3 2025), 13704000.0 (Q2 2025), and 16556000.0 (Q1 2025).